Coya Therapeutics, Inc. Cash Flow Statement
COYA|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Coya Therapeutics, Inc. used $11M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$21.2M | -$8.0M | -$12.2M |
| Depreciation & Amortization | - | $27.4K | $27.4K |
| Operating Cash Flow | -$10.7M | -$11.2M | -$7.2M |